Neoleukin Therapeutics to Host Investor R&D Showcase Highlighting De Novo Protein Therapeutics
SEATTLE, June 15, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will host a virtual Investor R&D Showcase on Tuesday, June 23, 2020 at 3:30 p.m. Pacific Time / 6:30 p.m. Eastern Time.
The event will feature an overview of presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting II as well as commentary from experts in the field of protein design and clinical development of IL-2 therapies.
Speakers will include:
- Jonathan Drachman, M.D. – Chief Executive Officer of Neoleukin
- David Baker, Ph.D. – Director of the University of Washington Institute for Protein Design, UW School of Medicine professor of biochemistry and a Howard Hughes Medical Institute investigator, Co-founder of Neoleukin and member of Scientific Advisory Board
- Michael Dougan, M.D., Ph.D. – Assistant Professor of Medicine at Harvard Medical School, Division of Gastroenterology at Massachusetts General Hospital and member of Neoleukin Scientific Advisory Board
- Nizar Tannir, MD, FACP – Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center
The live webcast event will include video and slide presentations and can be accessed from the investors section of the Neoleukin website at http://investor.neoleukin.com/events. An archived replay will also be available on the company website for at least 30 days following the event.
To RSVP for the event and add it to your calendar, please click here.
About Neoleukin Therapeutics, Inc.
Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.
Safe Harbor / Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, planned development activities and timelines, use and adequacy of cash reserves and the potential benefits of the company’s product candidates and platform. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Examples of such forward-looking statements include but are not limited to statements regarding the therapeutic properties and potential of the company’s de novo protein design technology. These statements are subject to numerous risks and uncertainties, including risks and uncertainties related to the company’s cash forecasts, the company’s ability to advance its product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, the timing of announcements and updates relating to the company’s clinical trials and related data market conditions and further impacts of COVID-19, that could cause actual results to differ materially from what Neoleukin expects. Further information on potential risk factors that could affect Neoleukin’s business and its financial results are detailed under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.